Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
Iranian rockets hit Tel Aviv area, injuring six - 2Palestinian infant freezes to death in Gaza as Israel keeps blocking aid
- 3Burger King launches 'SpongeBob' menu ahead of film's release. A look at the Bikini Bottom-inspired meal, plus what taste testers are saying.
- 4Landslides triggered by heavy rainfall kill at least 20 people in Tanzania
- 5She loves to give experiences. He goes for sentimental gifts. They ask an expert: What is the perfect holiday present?
- UK forecast to face weaker growth and higher inflation from Iran war
- Will your baby get a hep B vaccine? What RFK panel's ruling means.
- Independence from the rat race: How to Save and Contribute Shrewdly
- Which Brilliant Home Gadget Can't You Reside Without?
- Parents who delay baby's first vaccines also likely to skip measles shots
- Equality requires universal draft, participation in economy and workforce, MK Liberman says
- Curl Up With Some Hot Chocolate And Watch Mighty Car Mods Explore Japan In A Honda City Turbo II
- At least 55 injured in Russia after train crashes, overturns
- Rocket shines under the northern lights | Space photo of the day for March 25, 2026
